| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/04/2002 | WO2001092320A3 Use a high-molecular-weight extracellular haemoglobin as blood substitute |
| 04/04/2002 | WO2001090306A3 Compositions and methods for modulating tumor specific expression |
| 04/04/2002 | WO2001088106A3 Novel deoxyribonucleside kinase enzyme multi-substrate variants |
| 04/04/2002 | WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/04/2002 | WO2001087263A3 Delivery systems for treatment of vascular disease |
| 04/04/2002 | WO2001085980A3 Enzymatic assays for screening anti-cancer agents |
| 04/04/2002 | WO2001085796A3 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
| 04/04/2002 | WO2001085784A3 POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF |
| 04/04/2002 | WO2001085184A3 Nontoxic vernix compositions and method of producing |
| 04/04/2002 | WO2001083689A3 PEPTIDES FROM FRAMESHIFT MUTATED DNA POLYMERASE δ GENE |
| 04/04/2002 | WO2001082954A3 Ceruloplasmin and uses thereof in neurodegenerative related conditions |
| 04/04/2002 | WO2001082945A3 The use of bacterial phage associated lysing enzymes for treating various illnesses |
| 04/04/2002 | WO2001082870A3 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
| 04/04/2002 | WO2001082862A3 P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof |
| 04/04/2002 | WO2001081588A3 2246, novel protein kinase molecules and uses therefor |
| 04/04/2002 | WO2001080882A3 Methods and compositions for eliciting an immune response |
| 04/04/2002 | WO2001080871A3 Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2 |
| 04/04/2002 | WO2001080830A3 Pharmacotherapeutic process and composition for central nervous system disorders |
| 04/04/2002 | WO2001079462A3 Nucleic acids encoding polypeptides having haloperoxidase activity |
| 04/04/2002 | WO2001077294A3 Hpv-specific short-mers |
| 04/04/2002 | WO2001077290A3 Polynucleotides encoding novel secreted proteins |
| 04/04/2002 | WO2001076622A3 Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof |
| 04/04/2002 | WO2001075067A3 Novel nucleic acids and polypeptides |
| 04/04/2002 | WO2001075024A3 A novel polypeptide, nf-e2-associated human factor 13 and the polynucleotide encoding the polypeptide |
| 04/04/2002 | WO2001074373A3 Hemoglobinase inhibitors and methods of use |
| 04/04/2002 | WO2001073060A3 18221, dual specificity phosphatase and uses thereof |
| 04/04/2002 | WO2001073051A3 46743 and 27417, novel human acyltransferase family members and uses therefor |
| 04/04/2002 | WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 04/04/2002 | WO2001073033A3 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 04/04/2002 | WO2001072846A3 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 04/04/2002 | WO2001072839A3 Human g-protein coupled receptors |
| 04/04/2002 | WO2001072829A3 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 04/04/2002 | WO2001072781A3 Human genes and expression products |
| 04/04/2002 | WO2001068837A3 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 04/04/2002 | WO2001066741A3 Kcnb: a novel potassium channel protein |
| 04/04/2002 | WO2001064896A3 Human enzyme molecules |
| 04/04/2002 | WO2001064227A3 Androgenic activity of eucommia ulmoides extracts |
| 04/04/2002 | WO2001062799A3 Method for inhibiting angiogenesis using molecules that enhance plasmin activity |
| 04/04/2002 | WO2001062792A3 Cancer treatment and prognosis involving hes-1 protein |
| 04/04/2002 | WO2001062778A3 Tumour-specific animal proteins |
| 04/04/2002 | WO2001059113A3 G-protein coupled receptor proteins and nucleic acids encoding same |
| 04/04/2002 | WO2001053352A3 Sperm specific proteins |
| 04/04/2002 | WO2001049715A3 Methods and compositions for inhibiting neoplastic cell growth |
| 04/04/2002 | WO2001049298A3 Novel therapeutic use of enoxaparin |
| 04/04/2002 | WO2001048231A3 Method of achieving persistent transgene expression |
| 04/04/2002 | WO2001034802A3 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 04/04/2002 | WO2001034182A3 Composition for treating respiratory tract infections containing menthol, eucalyptol and an alpha-amylase |
| 04/04/2002 | WO2001012777A9 Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| 04/04/2002 | WO2001012232A3 Process to make a sustained release formulation |
| 04/04/2002 | WO2000072021A3 Cancer associated antigens and uses therefor |
| 04/04/2002 | WO2000070099A3 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 04/04/2002 | WO2000064261A9 Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof |
| 04/04/2002 | WO2000058359A9 Retro-inverso prosaposin-derived peptides and use thereof |
| 04/04/2002 | US20020040483 Contacting a test compound to a nematode; and monitoring a female sexual maturation of the nematode, wherein inhibition of the female sexual maturation indicates that the test compound includes the anti-nematode agent |
| 04/04/2002 | US20020040203 Method for transdermal or intradermal delivery of molecules |
| 04/04/2002 | US20020040144 For therapy of thrombotic disease, asthma, emphysema, cirrhosis, arthritis, carcinoma, melanoma, restenois, atheroma, trauma, shock and reperfusion injury |
| 04/04/2002 | US20020040128 Carbohydrate-blood protein complex for us as an oxygen transporter |
| 04/04/2002 | US20020040127 Nucleotide sequences which code tumor protein for use in diagnosis, prevention and treament of tumors |
| 04/04/2002 | US20020040015 Administering to the mammal an anti-angiogenesis factor and a photosensitizer to permit to localize in the chorodial neovasculature, irradiating the chorodial neovasculature with laser light |
| 04/04/2002 | US20020040009 Novel ratA |
| 04/04/2002 | US20020040008 Administering agent for inhibiting interaction between P-selectin and a ligand of P-selectin |
| 04/04/2002 | US20020040004 Administering to mammal a mixture of proteins derived from ground bone to provide increased blood flow to tissue served by an occluded or partly occluded vessel |
| 04/04/2002 | US20020040001 Pharmaceutical compositions comprising a soluble laminin receptor precursor or a compound which blocks the interaction of the laminin receptor precursor and PrPSc or PrPc |
| 04/04/2002 | US20020040000 Human kcnq5 potassium channel, methods and compositions thereof |
| 04/04/2002 | US20020039999 Antinociceptive agent derivative |
| 04/04/2002 | US20020039998 Administering to human therapeutically effective amount of a combination of drug which is metabolized by cytochrome p450 monooxygenase or pharmaceutically acceptable salt thereof and ritonavir |
| 04/04/2002 | US20020039997 Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
| 04/04/2002 | US20020039996 Pharmaceutical administration form for peptides, process for its preparation, and use |
| 04/04/2002 | US20020039995 Administering to mammal in need of such treatment a therapeutically effective amount of a trkB or trkC agonist |
| 04/04/2002 | US20020039992 Tek antagonists |
| 04/04/2002 | US20020039791 Methods and compositions for inhibiting thrombin generation at the surface of cells |
| 04/04/2002 | US20020039776 Mammalian SUV39H2 proteins and isolated DNA molecules encoding them |
| 04/04/2002 | US20020039774 Anticholesterol agents |
| 04/04/2002 | US20020039764 Nucleic, acids, proteins, and antibodies |
| 04/04/2002 | US20020039762 26908 novel G protein-coupled receptors and uses therefor |
| 04/04/2002 | US20020039760 Nucleotide sequences coding preferential polypeptides for use in treatment of blood disorders, cancer and thrombocytopenia |
| 04/04/2002 | US20020039759 Polypeptide for use in the prevention of bacterial infection |
| 04/04/2002 | US20020039756 Evaluation and classification of toxicity in humans; obtain samples, incubate with antibodies, detect bound complexes, increased concentration of bound complexes indicates toxicity in humans |
| 04/04/2002 | US20020039755 Conjugate vaccine against gram-negative bacterial infections |
| 04/04/2002 | US20020039748 Protein; for use in the treatment of blood disorders; for prevention of infection; wound healing agent |
| 04/04/2002 | US20020039745 Anti-inflammatory compositions and method |
| 04/04/2002 | US20020039741 Antitumor agent |
| 04/04/2002 | US20020039736 Reacting aliphatic aminonitrile with water in presence of solid alumina catalyst to form lactam |
| 04/04/2002 | US20020039735 Monoclonal antibodies to ING1 isoforms |
| 04/04/2002 | US20020039734 Detecting preferential lymphocytes in sample; obtain lymphocyte, compare concentration of markers with wild type, adjustment in concentration of markers indicates presence of helper lymphocytes |
| 04/04/2002 | US20020039731 Nucleotide sequences for use in the diagnosis, detection and treatment of cancer |
| 04/04/2002 | US20020039599 Calibration; administering antiseptic compound |
| 04/04/2002 | US20020039590 Nontoxic vernix compositions and method of producing |
| 04/04/2002 | US20020039585 Mutants of streptococcal toxin c and methods of use |
| 04/04/2002 | US20020039583 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 04/04/2002 | US20020039580 Method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification |
| 04/04/2002 | US20020039578 Methods for treating disease with antibodies to CXCR3 |
| 04/04/2002 | US20020039577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes |
| 04/04/2002 | US20020039576 Controller lymphocytes |
| 04/04/2002 | US20020039575 Supplying polypepties |
| 04/04/2002 | US20020039574 Delivery of therapeutic gene products by intestinal cell expression |
| 04/04/2002 | US20020039570 Interferons |
| 04/04/2002 | US20020039568 Genetic engineering |
| 04/04/2002 | DE10045621A1 Treating hepatitis B and C comprises administration of prothymosin alpha |
| 04/04/2002 | DE10045591A1 Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) Site-specific, antibody-mediated activation of proapoptotic cytokines - Amaize (Antibody Mediated Apoptosis Inducing cytokines) |